Both TCR and CAR-T therapy involve engineering T cells to fight cancer, but they differ in their mechanisms. CAR-T therapy uses chimeric antigen receptors that are designed to recognize proteins on the surface of cancer cells, primarily used in blood cancers. In contrast, TCR therapy relies on T cell receptors that can detect a broader range of antigens, including those presented by intracellular proteins, making it potentially applicable to a wider variety of cancers, including solid tumors.
